BioCryst Pharmaceuticals Inc. (BCRX)
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BioCryst: Orladeyo's Expansion Is Just Getting Started
BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO, a healthy cash position, and a promising pipeline, making it an attractive investment. Despite a net loss, BioCryst's improved operating metrics and strategic focus on key assets like BCX17725 and avoralstat signal disciplined resource allocation and long-term growth. ORLADEYO's potential pediatric expansion could significantly boost market penetration and revenue, positioning BioCryst as a leader in hereditary angioedema treatment.
BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up
BioCryst Pharmaceuticals stock rose 9% since September, driven by strong Orladeyo sales and raised revenue guidance for 2025 to $535-$550 million. Orladeyo's convenience over injectable therapies is solidifying its market presence, with pediatric expansion and exclusivity until 2035 boosting growth prospects. Potential competition from Pharvaris' deucrictibant, but Orladeyo's market entrenchment and differentiation mitigate immediate threats.
BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical
I initially rated BioCryst a "Sell" in November 2023, but am now upgrading to "Hold" as the company has outperformed my expectations, despite competitive pressures. Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition and may not reach management's $1bn annual revenue target in my view. Q4 2024 earnings showed a notable improvement with a reduced GAAP operating loss and a positive non-GAAP operating profit, but guidance for ~22% growth led to a sell-off.
Why BioCryst Pharmaceuticals Stock Tumbled by 10% Today
Investors clearly weren't in a forgiving mood on Monday when it came to BioCryst Pharmaceuticals (BCRX -9.99%) stock. After the commercial-stage biotech published its fourth-quarter and full-year 2024 results, they traded its shares down by an even 10% on the day.
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX ) Q4 2024 Earnings Conference Call February 24, 2025 8:30 AM ET Company Participants John Bluth - Chief Communications Officer Jon Stonehouse - CEO Charlie Gayer - Chief Commercial Officer Helen Thackray - Chief R&D Officer Anthony Doyle - CFO Conference Call Participants Tazeen Ahmad - Bank of America Jessica Fye - JP Morgan Stacy Ku - TD Cowen Brian Abrahams - RBC Capital Markets Gena Wang - Barclays Jonathan Wolleben - Citizens JMP Seema Sheoran - Evercore ISI Serge Belanger - Needham & Company Maury Raycroft - Jefferies Operator Good morning, and welcome to the BioCryst Fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode.
BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings
On Monday, BioCryst Pharmaceuticals, Inc. BCRX released results from an interim analysis of the ongoing APeX-P trial.
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.28 per share a year ago.
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy
BioCryst remains a "Buy" due to ORLADEYO's proven success, potential growth, and management's confidence despite significant competition and a one-dimensional revenue stream. Q3 2024 showed mixed results with a modest revenue beat and slight earnings miss, leading to a 13% stock drop on higher volume. ORLADEYO's revenue guidance is strong, with expectations of reaching $1 billion annually by 2029, driven by its convenience and efficacy.
